The DAPT Score Uncouples Bleeding and Ischemic Risk…Again.
作者信息
Yeh Robert W, Mihatov Nino
机构信息
Richard and Susan Smith Center for Outcomes Research in Cardiology, Division of Cardiology, Beth Israel Deaconess Medical and Harvard Medical School, Boston, Massachusetts.
Richard and Susan Smith Center for Outcomes Research in Cardiology, Division of Cardiology, Beth Israel Deaconess Medical and Harvard Medical School, Boston, Massachusetts; Division of Cardiology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.
出版信息
JACC Cardiovasc Interv. 2020 Mar 9;13(5):647-650. doi: 10.1016/j.jcin.2020.01.211.
Abstract
摘要
相似文献
1
The DAPT Score Uncouples Bleeding and Ischemic Risk…Again.
JACC Cardiovasc Interv. 2020 Mar 9;13(5):647-650. doi: 10.1016/j.jcin.2020.01.211.
2
DAPT Score and the Impact of Ticagrelor Monotherapy During the Second Year After PCI.
JACC Cardiovasc Interv. 2020 Mar 9;13(5):634-646. doi: 10.1016/j.jcin.2019.12.018.
3
Comparative Methodological Assessment of the Randomized GLOBAL LEADERS Trial Using Total Ischemic and Bleeding Events.
Circ Cardiovasc Qual Outcomes. 2020 Aug;13(8):e006660. doi: 10.1161/CIRCOUTCOMES.120.006660. Epub 2020 Jul 30.
4
Long versus short dual antiplatelet therapy in acute coronary syndrome patients treated with prasugrel or ticagrelor and coronary revascularization: Insights from the RENAMI registry.
Eur J Prev Cardiol. 2020 May;27(7):696-705. doi: 10.1177/2047487319836327. Epub 2019 Mar 12.
5
High bleeding risk patients with acute coronary syndromes treated with contemporary drug-eluting stents and Clopidogrel or Ticagrelor: Insights from CHANGE DAPT.
Int J Cardiol. 2018 Oct 1;268:11-17. doi: 10.1016/j.ijcard.2018.03.116. Epub 2018 May 23.
6
Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis.
Clin Pharmacol Ther. 2021 Aug;110(2):424-431. doi: 10.1002/cpt.2226. Epub 2021 Mar 23.
7
Comparison of one-month versus twelve-month dual antiplatelet therapy after implantation of drug-eluting stents guided by either intravascular ultrasound or angiography in patients with acute coronary syndrome: rationale and design of prospective, multicenter, randomized, controlled IVUS-ACS and ULTIMATE-DAPT trial.
Am Heart J. 2021 Jun;236:49-58. doi: 10.1016/j.ahj.2021.02.014. Epub 2021 Feb 20.
8
Prediction of Ischemic and Bleeding Events Using the Dual Antiplatelet Therapy Score in an Unrestricted Percutaneous Coronary Intervention Population.
Circ Cardiovasc Interv. 2018 Oct;11(10):e006853. doi: 10.1161/CIRCINTERVENTIONS.118.006853.
9
Comparative external validation of the PRECISE-DAPT and PARIS risk scores in 4424 acute coronary syndrome patients treated with prasugrel or ticagrelor.
Int J Cardiol. 2020 Feb 15;301:200-206. doi: 10.1016/j.ijcard.2019.11.132. Epub 2019 Nov 22.
10
Safety and Efficacy of 1-Month Dual Antiplatelet Therapy (Ticagrelor + Aspirin) Followed by 23-Month Ticagrelor Monotherapy in Patients Undergoing Staged Percutaneous Coronary Intervention (A Sub-Study from GLOBAL LEADERS).
Am J Cardiol. 2021 Jan 1;138:1-10. doi: 10.1016/j.amjcard.2020.09.057. Epub 2020 Oct 13.
引用本文的文献
1
Five-Year Prognostic Value of DAPT Score in Older Patients undergoing Percutaneous Coronary Intervention: A Large-Sample Study in the Real World.
J Atheroscler Thromb. 2023 Aug 1;30(8):1057-1069. doi: 10.5551/jat.64212. Epub 2023 May 30.
2
Acute Coronary Syndrome, Antiplatelet Therapy, and Bleeding: A Clinical Perspective.
J Clin Med. 2020 Jul 1;9(7):2064. doi: 10.3390/jcm9072064.
本文引用的文献
1
Ticagrelor Alone Versus Dual Antiplatelet Therapy From 1 Month After Drug-Eluting Coronary Stenting.
J Am Coll Cardiol. 2019 Nov 5;74(18):2223-2234. doi: 10.1016/j.jacc.2019.08.1038.
2
Validation of the DAPT score in real-world patients undergoing coronary stent implantation.
Int J Cardiol. 2020 Feb 1;300:99-105. doi: 10.1016/j.ijcard.2019.08.044. Epub 2019 Aug 21.
3
Prediction of Ischemic and Bleeding Events Using the Dual Antiplatelet Therapy Score in an Unrestricted Percutaneous Coronary Intervention Population.
Circ Cardiovasc Interv. 2018 Oct;11(10):e006853. doi: 10.1161/CIRCINTERVENTIONS.118.006853.
4
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial.
Lancet. 2018 Sep 15;392(10151):940-949. doi: 10.1016/S0140-6736(18)31858-0. Epub 2018 Aug 27.
5
External Validation of the DAPT Score in a Nationwide Population.
J Am Coll Cardiol. 2018 Sep 4;72(10):1069-1078. doi: 10.1016/j.jacc.2018.06.023.
6
Validating Utility of Dual Antiplatelet Therapy Score in a Large Pooled Cohort From 3 Japanese Percutaneous Coronary Intervention Studies.
Circulation. 2018 Feb 6;137(6):551-562. doi: 10.1161/CIRCULATIONAHA.117.028924. Epub 2017 Oct 5.
7
2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS).
Eur Heart J. 2018 Jan 14;39(3):213-260. doi: 10.1093/eurheartj/ehx419.
8
Validation of the DAPT score in patients randomized to 6 or 12 months clopidogrel after predominantly second-generation drug-eluting stents.
Thromb Haemost. 2017 Oct 5;117(10):1989-1999. doi: 10.1160/TH17-02-0101. Epub 2017 Jul 27.
9
Use of the Dual-Antiplatelet Therapy Score to Guide Treatment Duration After Percutaneous Coronary Intervention.
Ann Intern Med. 2017 Jul 4;167(1):17-25. doi: 10.7326/M16-2389. Epub 2017 Jun 13.
10
2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
J Am Coll Cardiol. 2016 Sep 6;68(10):1082-115. doi: 10.1016/j.jacc.2016.03.513. Epub 2016 Mar 29.
Zotero 插件